POM-V Prescription Required

Bovalto Respi 4 Suspension for Injection

Active ingredients: Bovine parainfluenza virus 3, Bovine respiratory syncytial virus, Bovine viral diarrhoea virus, Mannheimia haemolytica

Form

Injection

Species

Cattle

Manufacturer

Boehringer Ingelheim Vetmedica GmbH

VMD MA No.

04491/3006

What it's used for

Onset of immunity: 10 days after vaccination Duration of immunity: 12 weeks after vaccination.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bovine parainfluenza virus 3...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bovalto Respi 4 Suspension for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Onset of immunity: 10 days after vaccination
Duration of immunity: 12 weeks after vaccination.

Dose: 2 ml administered subcutaneously.
Warm before use to a temperature of 15 °C to 25 °C and shake the contents of the
bottle.
Primary vaccination
Calves from non-immune dams: two doses three weeks apart from 2 weeks of age.
For calves from immune dams or where the immune status of the dam is unknown,
the vaccination scheme should be adapted at the discretion of the veterinarian to
take into account potential interference of maternally derived antibodies with the
response to vaccination.
Revaccination
Administer one dose six months after completion of the primary vaccination scheme.
The efficacy of revaccination was demonstrated by measurement of the serological
response and has not been assessed by challenge.

None.

Cattle:
Very common
(>1 animal / 10 animals treated):
Injection site swelling*
Common
(1 to 10 animals / 100 animals treated):
Hyperthermia**Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Anaphylactic-type reactions***
Injection site pain****
* This swelling could reach up to 10 cm or more in diameter and may be associated
with pain, and usually progressively reduces and disappears within 6 weeks after
vaccination.
** Transient and slight, higher after the second injection (1.5°C at most) lasting up to
3 days after vaccination.
*** Appropriate symptomatic treatment should be administered.
**** Associated with injection site swelling.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Vaccinate healthy animals only.

Special precautions for safe use in the target species:
Safety and efficacy studies were performed in sero-negative calves. The efficacy of
the vaccination has not been demonstrated in presence of antibodies. The level of
antibody response may be reduced by the presence of maternal antibodies. In the
presence of maternal antibodies, timing of initial vaccination of calves should be
planned accordingly.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case-by-
case basis.

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze. Protect from light.

Zero days.
4. IMMUNOLOGICAL INFORMATION
4.1 ATCvet code: QI02AL.
The vaccine induces an active immunity against bovine respiratory syncytial virus,
parainfluenza 3 virus, bovine viral diarrhoea virus and Mannheimia haemolytica
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.